In honor of World Cancer Day 2015, the Bonnie J. Addario Lung Cancer Foundation and Free To Breathe, with support from Celgene and Genentech, created the Clinical Trial Innovation Prize. The ultimate goal of the challenge is to produce a breakthrough that doubles the accrual rate of lung cancer clinical trials. We couldn’t be happier to have been selected as one of 12 finalists and awarded one of the first three prizes in “Ideation” phase of the program.
The Clinical Trial Innovation Prize sponsors were looking for innovative ideas to dramatically increase the number of cancer patients participating in trials – currently, only 3% of cancer patients participate, despite the fact that cancer is one of the leading causes of death worldwide, with the number of new cases expected to rise by approximately 70% over the next two decades.
At Science 37, our mission is to transform the clinical research process – to accelerate biomedical discovery and reduce clinical trial costs, so we were thrilled to be able to participate in this challenge. The sponsors identified lack of awareness and fear of time or financial burdens as significant factors in low research participation rates – factors that Science 37 is uniquely positioned to address. We use patient-centered technology to simplify the process of participating in trials and connect patients safely and securely to the world’s best scientists, no matter where they live. We recruit and enroll patients directly, through their mobile phones, tablets, or home computers, and we bring research to patients at home – dramatically reducing time and travel costs.
“The winning ideas embrace technology, which is a must in today’s healthcare landscape, but they do more than that, they engage the patient,” said Sherie Reinders, chief operating officer at Free to Breathe. “Engaging cancer patients and making it easy for them to find and participate in trials will help break down one of the biggest barriers we face today and that’s awareness that trials even exist.”
Among the 47 submissions to the HeroX Innovation challenge, Science 37 received the most public support, and we are proud to have been awarded one of the three prizes in the first phase of the Challenge. We look forward to the next phase of the Challenge, and congratulate all the applicants and winners. We would like to thank The Bonnie J. Addario Lung Cancer Foundation, Free to Breathe, Celgene and Genentech for creating this important framework for spotlighting innovation in clinical research. You can read more about the Clinical Trial Innovation Prize at the Free to Breathe website.